EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Clinical efficacy and safety of intravenous ferric carboxymaltose for treatment of restless legs syndrome: a multicenter, randomized, placebo-controlled clinical trial

Christopher J Earley, Diego García-Borreguero iD, Mark Falone, John W Winkelman

SLEEP · 2024

DOI: 10.1093/sleep/zsae095 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift SLEEP, 2024. Verfasst von Christopher J Earley und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Restless Legs Syndrome, Ferric Compounds, Maltose. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study Objectives Iron therapy is associated with improvements in restless legs syndrome (RLS). This multicenter, randomized, double-blind study evaluated the effect of intravenous ferric carboxymaltose (FCM) on RLS.

Methods

A total of 209 adult patients with a baseline International RLS (IRLS) score ≥ 15 were randomized (1:1) to FCM (750 mg/15 mL) or placebo on study days 0 and 5. Ongoing RLS medication was tapered starting on Day 5, with the goal of discontinuing treatment or achieving the lowest effective dose. Co-primary efficacy endpoints were changed from baseline in IRLS total score and the proportion of patients rated as much/very much improved on the Clinical Global Impression (CGI)–investigator (CGI-I) scale at day 42 in the “As-Treated” population.

Results

The “As-Treated” population comprised 107 FCM and 101 placebo recipients; 88 (82.2%) and 68 (67.3%), respectively, completed the day 42 assessment. The IRLS score reduction was significantly greater with FCM versus placebo: least-squares mean (95% confidence interval [CI]) −8.0 (−9.5, −6.4) versus −4.8 (−6.4, −3.1); p = .0036. No significant difference was observed in the proportion of FCM (35.5%) and placebo (28.7%) recipients with a CGI-I response (odds ratio 1.37 [95% CI: 0.76, 2.47]; p = .2987). Fewer patients treated with FCM (32.7%) than placebo (59.4%) received RLS interventions between day 5 and study end (p = .0002). FCM was well tolerated.

Conclusions

The IRLS score improved with intravenous FCM versus placebo, although the combination of both co-primary endpoints was not met. Potential methodological problems in the study design are discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Restless Legs SyndromeFerric CompoundsMaltoseHumansMaleFemaleDouble-Blind MethodMiddle AgedTreatment OutcomeAdultAgedAdministration, Intravenous

Stichwörter der Autor:innen

ferric carboxymaltoseiron repletionrestless legs syndromerestless legs syndrome—clinical assessmentrestless legs syndrome—neurobiology

Substanzen

ferric carboxymaltoseFerric CompoundsMaltose

Autor:innen und Institutionen

  • Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
  • Sleep Research Institute, Madrid, Spain.
  • American Regent, Inc., Clinical Research and Development, Shirley, NY, USA.
  • Departments of Psychiatry and Neurology, Massachusetts General Hospital, Boston, MA, USA.

ORCID-Profile: Diego García-Borreguero

Zitieren

APA

Earley, C. J., García-Borreguero, D., Falone, M., & Winkelman, J. W. (2024). Clinical efficacy and safety of intravenous ferric carboxymaltose for treatment of restless legs syndrome: a multicenter, randomized, placebo-controlled clinical trial. SLEEP. https://doi.org/10.1093/sleep/zsae095

Vancouver

Earley CJ, García-Borreguero D, Falone M, Winkelman JW. Clinical efficacy and safety of intravenous ferric carboxymaltose for treatment of restless legs syndrome: a multicenter, randomized, placebo-controlled clinical trial. SLEEP. 2024. doi:10.1093/sleep/zsae095

BibTeX
@article{Earley2024,
  author = {Earley, Christopher J and García-Borreguero, Diego and Falone, Mark and Winkelman, John W},
  title = {Clinical efficacy and safety of intravenous ferric carboxymaltose for treatment of restless legs syndrome: a multicenter, randomized, placebo-controlled clinical trial},
  journal = {SLEEP},
  year = {2024},
  doi = {10.1093/sleep/zsae095}
}
Kostenlos starten →